Secukinumab improves the quality‐of‐life of family members and partners of people with psoriasis: Family Dermatology Life Quality Index (FDLQI) results from a randomised open‐label study (SIGNATURE)

Secukinumab improves the quality‐of‐life of family members and partners of people with psoriasis: Family Dermatology Life Quality Index (FDLQI) results from a randomised open‐label study (SIGNATURE)

Abstract Background The Family Dermatology Life Quality Index (FDLQI) was developed to meet a need for a dermatology‐specific family member/partner quality‐of‐life (QoL) measure. This paper focuses on the analysis and interpretation of FDLQI data (used as an exploratory outcome) collected in the SIG...

Full description

Bibliographic Details
Main Authors: A. Y. Finlay, J. N. Barker, A. D. Burden, C. E. M. Griffiths, B. Kirby, M. L. Goodman, C. Neill, R. B. Warren
Format: Article
Language:English
Published: Wiley 2022-09-01
Series:JEADV Clinical Practice
Subjects:
family members/partners
FDLQI
psoriasis
quality‐of‐life
secukinumab
Online Access:https://doi.org/10.1002/jvc2.42

Internet

https://doi.org/10.1002/jvc2.42

Similar Items